Patents Assigned to Eternity Bioscience Inc.
  • AMINOPYRIDAZINONE COMPOUNDS AS PROTEIN KINASE INHIBITORS
    Publication number: 20170152264
    Abstract: The present disclosure provides a compound of formula (I) and the use thereof for the therapeutic treatment of human cancers including B-cell lymphoma and autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis.
    Type: Application
    Filed: October 20, 2014
    Publication date: June 1, 2017
    Applicant: ETERNITY BIOSCIENCE INC.
    Inventors: Dong LIU, Minsheng ZHANG, Qiyue HU
  • SUBSTITUTED ETHYNYL HETEROBICYCLIC COMPOUNDS AS TYROSINE KINASE INHIBITORS
    Publication number: 20170114063
    Abstract: The present disclosure provides a compound of formula (I) and the use thereof for the therapeutic treatment of human cancers including B-cell lymphoma and autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis.
    Type: Application
    Filed: October 20, 2014
    Publication date: April 27, 2017
    Applicant: ETERNITY BIOSCIENCE INC.
    Inventors: Minsheng Zhang, Yinfa YAN
  • Furanone compounds as kinase inhibitors
    Patent number: 9458140
    Abstract: The present disclosure provides novel furanone compounds, or pharmaceutically acceptable salts, solvates or prodrugs thereof, as Raf kinase, especially BRAF kinase, inhibitors, which are useful therapeutic agents for treatment of Raf kinase related diseases or disorders, such as melanomas, cancers, and leukemia. The disclosure also provides methods and processes for preparing these novel furanone compounds, pharmaceutical compositions containing these furanone compounds, and methods of treatment using these furanone compounds.
    Type: Grant
    Filed: May 8, 2014
    Date of Patent: October 4, 2016
    Assignee: Eternity Bioscience Inc.
    Inventors: Dong Liu, Minsheng Zhang
  • Aminoisoquinoline Derivatives as Protein Kinase Inhibitors
    Publication number: 20160257676
    Abstract: The present invention provides novel aminoisoquinoline compounds as defined in the specification, compositions thereof use of these compounds as protein kinase inhibitors and as therapeutic agents for treatment of Raf kinase, in particular BRAFV600E kinase, related diseases or disorders, such as cancers. In addition, the invention also includes methods and processes for preparing these novel aminoisoquinoline compounds.
    Type: Application
    Filed: September 12, 2013
    Publication date: September 8, 2016
    Applicant: ETERNITY BIOSCIENCE INC.
    Inventors: Minsheng Zhang, Dong Liu, Biao Lu
  • Furanone Compounds as Kinase Inhibitors
    Publication number: 20160096825
    Abstract: The present disclosure provides novel furanone compounds, or pharmaceutically acceptable salts, solvates or prodrugs thereof, as Raf kinase, especially BRAF kinase, inhibitors, which are useful therapeutic agents for treatment of Raf kinase related diseases or disorders, such as melanomas, cancers, and leukemia. The disclosure also provides methods and processes for preparing these novel furanone compounds, pharmaceutical compositions containing these furanone compounds, and methods of treatment using these furanone compounds.
    Type: Application
    Filed: May 8, 2014
    Publication date: April 7, 2016
    Applicant: ETERNITY BIOSCIENCE INC.
    Inventors: Dong Liu, Minsheng Zhang
  • QUINAZOLINEDIONES AND THEIR USE
    Publication number: 20140031358
    Abstract: The present invention discloses compounds of formula (I), or pharmaceutically acceptable salts or prodrugs thereof, which inhibit the poly(ADP-ribose) polymerases (PARP) and therefore are useful for treating diseases, disorders, and conditions related to PARP. The present invention also discloses pharmaceutical compositions comprising a compound of formula (I), and methods of using such compounds to inhibit PARP enzymes, and to treat diseases, disorders, and conditions related to PARP.
    Type: Application
    Filed: March 12, 2012
    Publication date: January 30, 2014
    Applicant: Eternity Bioscience Inc.
    Inventors: Dong Liu, Minsheng Zhang, Kan He, Lianshan Zhang
  • PHOSPHORUS CONTAINING COMPOUNDS AS PROTEIN KINASE INHIBITORS
    Publication number: 20120220551
    Abstract: The present invention relates to compounds represented by formula (I), which can modulate the activity of protein kinases. The invention also relates to a composition containing a compound of formula (I), and a method for synthesizing and using such compound for preventing or treating ALK or cMet mediated disorders or conditions.
    Type: Application
    Filed: February 22, 2012
    Publication date: August 30, 2012
    Applicant: Eternity Bioscience Inc.
    Inventors: Baihua Hu, Kan He, Minsheng Zhang